

# Levels of Evidence for Published Papers of the Barricaid device for annulus fibrosus closure

Study	Ref.	Level	Notes
<b>LEVEL I EVIDENCE</b>			
Meta-analysis of randomized trials	1	Ia	
554-patient randomized trial	2-16	Ib	
60-patient randomized trial	17	Ib	
<b>LEVEL II EVIDENCE</b>			
Network meta-analysis	18	IIb	Systematic review of Level IIIb evidence; upgraded since a SR is rated higher than the underlying evidence.
Meta-analysis of controlled studies	19	IIb	Systematic review of Level IIIb evidence; upgraded since a SR is rated higher than the underlying evidence.
Krutko Cohort Study	20	IIb	
Superiority Claims: Systematic Review	21	IIb	
<b>LEVEL III EVIDENCE</b>			
ISASS Policy Guideline	22	IIIb	
Systematic review of Barricaid results	23	IIIb	Systematic review of Level IV evidence; upgraded since a SR is rated higher than the underlying evidence.
Cohort A controlled study	23,24,25,26	IIIb	
Cohort B controlled study	27	IIIb	
Combined Cohort A & B controlled study	28	IIIb	
<b>LEVEL IV EVIDENCE</b>			
Cohort A case series	29	IV	
Combined cohort A & B case series	30,31	IV	
Ardeshiri case series	32,33	IV	
Kursumovic case series	34,35	IV	
Martens case series	36	IV	
Sanginov case series	37	IV	
Kienzler RCT + case series	38	IV	
<b>LEVEL V EVIDENCE</b>			
Gautschi case report	39	V	
Hahn case report	40	V	
Krutko case report	41	V	
Lange case report	42	V	
Barth letter to editor	43	V	
Bouma letter to editor	44	V	
Grasso letter to editor	45	V	
Izci letter to editor	46	V	
Klassen letter to editor	47	V	
Lange letter to editor	48	V	
Shiban letter to editor	49	V	
Burkhardt case report	50	V	
Castro editorial	51	V	

UNGRADED EVIDENCE			
Ammerman WC reoperation study	52		
Ament health economics study (a)	53		
Ament health economics study (b)	54		
Bostelmann health economics study	55		
Klassen health economics study	56		
Parker health economics study	57		
Thaci health economics study	58		
554-patient randomized trial protocol paper	59		
US case series protocol paper	60		
Bostelmann preclinical paper	61		
Wilke preclinical paper	62		

*Grading scale: Oxford Centre for Evidence-Based Medicine Levels of Evidence*

These articles contain off-label use information. Please use medical discretion when reviewing these articles.

---

**Barricaid is approved for the following indications for use:**

Reducing the incidence of reherniation and reoperation in skeletally mature patients with radiculopathy (with or without back pain) attributed to a posterior or posterolateral herniation, and confirmed by history, physical examination and imaging studies which demonstrate neural compression using MRI to treat a large annular defect (between 4-6 mm tall and between 6-10 mm wide) following a primary discectomy procedure (excision of herniated intervertebral disc) at a single level between L4 and S1.

---

**Financial disclosure:**

One or more authors have received financial compensation from Intrinsic Therapeutics. Full financial disclosures can be found in the respective manuscripts.